M
Muneer H. Abidi
Researcher at Michigan State University
Publications - 108
Citations - 3742
Muneer H. Abidi is an academic researcher from Michigan State University. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 27, co-authored 103 publications receiving 3097 citations. Previous affiliations of Muneer H. Abidi include Spectrum Health & Washington University in St. Louis.
Papers
More filters
Journal ArticleDOI
Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial
Brian G.M. Durie,Antje Hoering,Muneer H. Abidi,S. Vincent Rajkumar,Joshua Epstein,Stephen P. Kahanic,Mohan C. Thakuri,Frederic J. Reu,Christopher M. Reynolds,Rachael Sexton,Robert Z. Orlowski,Bart Barlogie,Angela Dispenzieri +12 more
TL;DR: This randomised, open-label, phase 3 trial aimed to study whether the addition of bortezomib to lenalidomide and dexamethasone would improve progression-free survival and provide better response rates in patients with previously untreated multiple myeloma who were not planned for immediate autologous stem-cell transplant.
Journal ArticleDOI
Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial
Craig H. Moskowitz,Auayporn Nademanee,Tamas Masszi,Edward Agura,Jerzy Holowiecki,Muneer H. Abidi,Andy I. Chen,Patrick J. Stiff,Alessandro M. Gianni,Angelo Michele Carella,Dzhelil Osmanov,Veronika Bachanova,John W. Sweetenham,Anna Sureda,Dirk Huebner,Eric L. Sievers,Andy Chi,Emily K. Larsen,Naomi N. H. Hunder,Jan Walewski +19 more
TL;DR: Early consolidation with brentuximab vedotin after autologous stem-cell transplantation improved progression-free survival in patients with Hodgkin's lymphoma with risk factors for relapse or progression after transplantation.
Journal ArticleDOI
High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study.
Richard A. Nash,Richard A. Nash,Peter A. McSweeney,Leslie J. Crofford,Muneer H. Abidi,Chien-Shing Chen,J. David Godwin,Ted Gooley,Ted Gooley,Leona Holmberg,Leona Holmberg,Gretchen Henstorf,C. Fred LeMaistre,Maureen D. Mayes,Kevin T. McDonagh,Bernadette McLaughlin,Jerry A. Molitor,J. Lee Nelson,J. Lee Nelson,Howard M. Shulman,Howard M. Shulman,Rainer Storb,Rainer Storb,Federico Viganego,Mark H. Wener,James R. Seibold,Keith M. Sullivan,Daniel E. Furst +27 more
TL;DR: Sustained responses including a decrease in dermal fibrosis were observed exceeding those previously reported with other therapies, and HDIT and autologous HCT for SSc should be evaluated in a randomized clinical trial.
Journal ArticleDOI
Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232)
Jeffrey A. Zonder,John Crowley,Mohamad A. Hussein,Vanessa Bolejack,Dennis F. Moore,Brock F. Whittenberger,Muneer H. Abidi,Brian G.M. Durie,Bart Barlogie +8 more
TL;DR: One-year progression-free survival, overall response rate, and very good partial response rate were superior with LEN-DEX, whereas 1-year overall survival was similar.
Journal ArticleDOI
Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse
Craig H. Moskowitz,Jan Walewski,Auayporn Nademanee,Tamás Masszi,Edward Agura,Jerzy Holowiecki,Muneer H. Abidi,Andy I. Chen,Patrick J. Stiff,Simonetta Viviani,Veronika Bachanova,Anna Sureda,Teresa McClendon,Connie Lee,Julie Lisano,John W. Sweetenham +15 more
TL;DR: Consolidation with BV in adult patients with cHL at high risk of relapse or progression after auto-HSCT confers a sustained PFS benefit and is safe and well tolerated.